<SEC-DOCUMENT>0001104659-22-087502.txt : 20220809
<SEC-HEADER>0001104659-22-087502.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220808215516
ACCESSION NUMBER:		0001104659-22-087502
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20220804
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		221146187

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2222857d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:apdn="http://adnas.com/20220804">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_apdn_adnas.com_20220804 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20220804_20220804 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0000744452 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityCentralIndexKey">0000744452</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="apdn-20220804.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-08-04to2022-08-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-04</xbrli:startDate>
        <xbrli:endDate>2022-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="margin: 0pt 0">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220804__20220804_zrkAUYw54ww6"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PURSUANT TO SECTION 13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_907_edei--DocumentPeriodEndDate_c20220804__20220804_zQTJ3CXPLla8"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 4, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20220804__20220804_z1AZK6oQmIHc"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityRegistrantName">Applied DNA Sciences, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220804__20220804_zNYbUeNlTDkh"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(State or other jurisdiction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">of incorporation)</p></td>
    <td style="width: 34%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityFileNumber_c20220804__20220804_zpuy4wLolun9"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityFileNumber">001-36745</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(Commission File Number)</p></td>
    <td style="width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220804__20220804_zvdprKWF4iFe"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityTaxIdentificationNumber">59-2262718</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(IRS Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220804__20220804_zlcdIE3bEuSa"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityAddressAddressLine1">50 Health Sciences Drive</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20220804__20220804_zLsyHrR36mfj"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityAddressCityOrTown">Stony Brook</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20220804__20220804_zWYG2V00KjYf"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220804__20220804_zBMBTwohvuAe"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:EntityAddressPostalZipCode">11790</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices; zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--CityAreaCode_c20220804__20220804_zlEclEt8NBIk"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:CityAreaCode">631</ix:nonNumeric></span>-<span id="xdx_90E_edei--LocalPhoneNumber_c20220804__20220804_zWEUuu7INag8"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:LocalPhoneNumber">240-8800</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20220804__20220804_zx7YS2wLXbD1"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20220804__20220804_zLLoUOaaJImk"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementTenderOffer_c20220804__20220804_zl1gge4eRJb1"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20220804__20220804_z1KArA52yco2"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20220804__20220804_zVtsxSWWTYTl"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font: 10pt Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 38%; text-align: center"><b>Title of each class</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><b>Trading Symbol(s)</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 38%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_904_edei--Security12bTitle_c20220804__20220804_zFZBCxyqiFUe"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_907_edei--TradingSymbol_c20220804__20220804_zFKahmA86qkk"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" name="dei:TradingSymbol">APDN</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">The <span id="xdx_904_edei--SecurityExchangeName_c20220804__20220804_z8XTRLhnBRRb"><ix:nonNumeric contextRef="From2022-08-04to2022-08-04" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Stock Market</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01. Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The information
regarding the Offering and the Agreement (each, as defined below) set forth in Item 8.01 of this Current Report on Form 8-K is incorporated
by reference into this Item 1.01.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01. Other Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2022, Applied DNA Sciences, Inc.
(the &#8220;<b><i>Company</i></b>&#8221;) <span style="background-color: white">completed a best efforts public offering (the &#8220;<b><i>Offering</i></b>&#8221;)
</span>with respect to the issuance and sale of<span style="background-color: white">: (i) </span>2,820,000 of shares (the &#8220;<b><i>Shares</i></b>&#8221;)
of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<b><i>Common Stock</i></b>&#8221;); (ii) 3,000,000 Series
A Common Stock purchase warrants to purchase 3,000,000 shares of Common Stock (the &#8220;<b><i>Series A Warrants</i></b>&#8221;) and
3,000,000 Series B Common Stock purchase warrants to purchase 3,000,000 shares of Common Stock (the &#8220;<b><i>Series B Warrants</i></b>
and, together with the Series A Warrants, the &#8220;<b><i>Series Warrants</i></b>&#8221;), each to purchase in the ratio of one to one
per Share of Common Stock; (iii) 180,000 pre-funded Common Stock purchase warrants (the &#8220;<b><i>Prefunded Warrants</i></b>&#8221;
and, together with the Series Warrants, the &#8220;<b><i>Warrants</i></b>&#8221;) to purchase 180,000 shares of Common Stock; and (iv)
the shares of Common Stock issuable from time to time upon exercise of the Prefunded Warrants and the Series Warrants (the &#8220;<b><i>Warrant
Shares</i></b>&#8221;, and together with the Prefunded Warrants, the Series Warrants and the Shares, the &#8220;<b><i>Securities</i></b>&#8221;),
pursuant to the terms described in the final prospectus and the terms of the Securities Purchase Agreement, dated August 4, 2022 (the
 &#8220;<b><i>Agreement</i></b>&#8221;) with <span style="background-color: white">certain institutional investors (the &#8220;<b><i>Purchasers</i></b>&#8221;)
identified on the signature pages thereto</span>. The Securities sold in the Offering consisted of: 2,820,000 Shares of Common Stock,
together with 180,000 Prefunded Warrants, 3,000,000 Series A Warrants and 3,000,000 Series B Warrants, of which 695,000 Shares of Common
Stock, 180,000 Prefunded Warrants, 875,000 Series A Warrants and 875,000 Series B Warrants were sold pursuant to the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series Warrants have an exercise price of
$4.00 <span style="background-color: white">per share of Common Stock.&#160;The Series A Warrants are exercisable upon issuance and will
expire five years from the date of issuance. The Series B Warrants are exercisable upon issuance and will expire thirteen months from
the date of issuance. The exercise price of the Series Warrants is subject to adjustment for stock splits, reverse splits, and similar
capital transactions as described in the Series Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Subject
to certain ownership limitations described in the Prefunded Warrants, the Prefunded Warrants are immediately exercisable and may be exercised
at a nominal consideration of $0.0001 per share&#160;of Common Stock any time until all of the Prefunded Warrants are exercised in full.
A holder will not have the right to exercise any portion of the Series Warrants or the Prefunded Warrants if the holder (together with
its affiliates) would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common
Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms
of the Series Warrants or the Prefunded Warrants, respectively.&#160;However, upon notice from the holder to the Company, the holder may
increase the beneficial ownership limitation, which may not exceed 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series Warrants or
the Prefunded Warrants, respectively, provided that any increase in the beneficial ownership limitation will not take effect until 61
days following notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">As
compensation to </span>H.C. Wainwright &amp; Co., LLC (the &#8220;<b><i>Placement Agent</i></b>&#8221;), as the exclusive placement in
connection with the Offering, the Company paid the Placement Agent <span style="background-color: white">a cash fee of 7% of the aggregate
gross proceeds raised in the Offering&#160;and reimbursement of certain expenses and legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In connection
with the Offering, as noted above, the Company entered into the Agreement with certain institutional investors on August 4, 2022. The
Agreement contains customary representations and warranties and agreements of the Company and the Purchasers and customary indemnification
rights and obligations of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The
shares of Common Stock, the Series Warrants and the Prefunded Warrants described above and the underlying shares of Common Stock were
offered pursuant to the Registration Statement on Form S-1, as amended (File No. 333-</span>266223<span style="background-color: white">),
which was declared effective by the Securities and Exchange Commission on August 4, 2022 and an additional registration statement on Form
S-1MEF filed pursuant to Rule 462(b) (File No. 333-</span>266512<span style="background-color: white">), which was filed on August 4,
2022 and became effective upon filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The
Company received net proceeds of approximately $11.1 million from the Offering, after deducting the estimated offering expenses
payable by the Company, including the Placement Agent fees. The Company intends to use the net proceeds from the Offering to further
the development of its </span>manufacture of DNA for use in nucleic acid-based therapeutics <span style="background-color: white">and </span>detection
of DNA in molecular diagnostics testing services<span style="background-color: white">, as well as general corporate purposes, which
may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and
potential acquisitions of or investments in businesses, products and technologies that complement its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summaries of the Offering in this Current
Report on Form 8-K and the terms of the Agreement, Series A Warrants, Series B Warrants and Prefunded Warrants are subject to, and qualified
in their entirety by such documents attached herewith as Exhibits 10.1, 4.1, 4.2 and 4.3, respectively, and are incorporated by reference
herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On August
4, 2022, the Company issued a press release announcing the pricing of the Offering. On August 8, 2022, the Company issued a press release
announcing the closing of the Offering. Copies of these press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and
are incorporated herein by reference.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report does not constitute an offer to sell
or the solicitation of an offer to buy, and these securities cannot be sold in any state or jurisdiction in which this offer, solicitation,
or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. Any offer will
be made only by means of a prospectus forming a part of the effective registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report contains forward-looking statements.
The statements made by Applied DNA in this report may be &#34;forward-looking&#34; in nature within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking
statements describe the Company&#8217;s future plans, projections, strategies, and expectations, and are based on assumptions and involve
a number of risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements include statements
relating to the offering, including the intended use of net proceeds therefrom and the potential exercise of the warrants. Actual results
could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance,
the possibility that Company&#8217;s testing services could become obsolete or have their utility diminished and the unknown amount of
revenues and profits that will results from Company&#8217;s testing services. Further, the uncertainties inherent in research and development,
future data and analysis, including whether any of Company&#8217;s current or future diagnostic candidates will advance further in the
research and/or validation process or receiving authorization, clearance or approval from the U.S. Food and Drug Administration (the &#8220;<b><i>FDA</i></b>&#8221;),
equivalent foreign regulatory agencies and/or the New York State Department of Health (&#8220;<b><i>NYSDOH</i></b>&#8221;), and whether
and when, if at all, they will receive final authorization, clearance or approval from the FDA, equivalent foreign regulatory agencies
and/or NYSDOH, the unknown outcome of any applications or requests to FDA, equivalent foreign regulatory agencies and/or the NYSDOH, disruptions
in the supply of raw materials and supplies, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology
approved for therapeutic use, and various other factors detailed from time to time in Company&#8217;s SEC reports and filings, including
its Annual Report on Form 10-K filed on December 9, 2021, as amended, its Quarterly Report on Form 10-Qs filed on February 10, 2022 and
May 12, 2022, and other reports the Company files with the SEC, which are available at www.sec.gov. The Company undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, unless otherwise required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01.&#160;&#160;&#160;Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<i>d) Exhibits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td style="width: 95%; padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Warrant.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Warrant.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></a></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Prefunded Warrant.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated August 4, 2022, by and between Applied DNA Sciences, Inc. and certain purchasers.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated August 4, 2022, announcing pricing of the Offering.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><a href="tm2222857d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><a href="tm2222857d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated August 8, 2022, announcing closing of the Offering.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding-top: 1.3pt; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 8, 2022</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 44%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4dU2SXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeShnGEqIkTRIo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB3xVJGw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2222857d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>EXHIBIT&nbsp;4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SERIES A COMMON STOCK
PURCHASE WARRANT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>applied
dna sciences, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Warrant Shares: _______</TD><TD STYLE="width: 0%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">Initial Exercise Date:
                                            _______, 2022</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES A COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New York City time) on _________,
2027<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Applied DNA Sciences,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1 </SUP>Insert the date that is the five year anniversary of
the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of _________, 2022, by and among the Company and the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-266223).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219 and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement
Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of
Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably
practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $_____, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(A)&nbsp;= as
applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(X)&nbsp;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take
any position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one
(1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00
p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase
Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on
the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that
payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to
purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
 &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount
obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with
the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at
the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. The obligation of the Company to pay compensation
for Buy-In under this Section&nbsp;2(d)(iv)&nbsp;is subject to delivery by the Holder of the aggregate Exercise Price in accordance with
the terms of Section&nbsp;2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination
and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other
than to the extent that information on the number of outstanding shares of Common Stock of the Company is provided by the Company and
relied upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder and the Company shall have
no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that
are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section&nbsp;2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%] of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental
Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled
to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black
Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company
in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof,
or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with
the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid
any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor
Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable contemplated Fundamental
Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period
equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B)&nbsp;an
expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental
Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per
share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction
and (ii)&nbsp;the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable
contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading
Day of the Holder&rsquo;s request pursuant to this Section&nbsp;3(d)&nbsp;and (D)&nbsp;a remaining option time equal to the time between
the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero
cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration)
within five Business Days of the Holder&rsquo;s election (or, if later, on the date of consummation of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Voluntary
Adjustments By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Company, at 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: <B>Beth Jantzen</B>, email address: beth.jantzen@adnas.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this
Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on a day that is not a Trading
Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is
required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on
Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>applied dna sciences, inc.</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 47%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Name:</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">applied
dna sciences, inc.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 17%">Name of Investing Entity:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 73%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing
    Entity:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 55%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Phone Number:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Email Address: </TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 35%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>tm2222857d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT&nbsp;4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SERIES B COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>APPLIED
DNA SCIENCES,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Warrant Shares: _______</TD><TD STYLE="width: 0%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">Initial Exercise Date:
                                            _______, 2022</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES B COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New York City time) on _________,
2023<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Applied DNA Sciences,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;1</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Insert the date that is the thirteen month anniversary
of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of _________, 2022, by and among the Company and the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-266223).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219 and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;2</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as
defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States
bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $_____, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(A)&nbsp;= as applicable:
(i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is
(1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed
and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as
defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the
option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(X)&nbsp;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any
position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof. The obligation of the Company to pay compensation for Buy-In under
this Section&nbsp;2(d)(iv)&nbsp;is subject to delivery by the Holder of the aggregate Exercise Price in accordance with the terms of Section&nbsp;2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership
shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the
number of outstanding shares of Common Stock of the Company is provided by the Company and relied upon by the Holder). In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange
Act and the rules&nbsp;and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy
of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership
Limitation. For purposes of this Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely
on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written
notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of
Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;3</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company's control,
including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>,
that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders
of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental
Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of
the day of consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day
immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per
share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the highest VWAP during the period
beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or
the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&rsquo;s request pursuant
to this Section&nbsp;3(d)&nbsp;and (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black
Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of
the Holder&rsquo;s election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities,
jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with
the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Voluntary
Adjustments By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;4</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to
the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;5</U>.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: <B>Beth Jantzen</B>, email address: beth.jantzen@adnas.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent
by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this
Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on a day that is not a Trading
Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is
required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on
Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>applied dna sciences, inc.</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 47%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Name:</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TO:</FONT><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">APPLIED
DNA SCIENCES,&nbsp;INC.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 17%">Name of Investing Entity:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 73%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing
    Entity:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 55%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Phone Number:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Email Address: </TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 35%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>tm2222857d1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT&nbsp;4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRE-FUNDED COMMON STOCK
PURCHASE WARRANT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>applied
dna sciences, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Warrant Shares: _______</TD><TD STYLE="width: 0%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">Initial
                                            Exercise Date: _______, 2022</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Applied DNA Sciences,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common
Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of _________, 2022, by and among the Company and the purchasers
signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-______).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219 and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement
Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of
Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably
practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any
circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination
Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(A)&nbsp;= as
applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">(X)&nbsp;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take
any position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to
purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
 &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount
obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with
the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at
the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. The obligation of the Company to pay compensation
for Buy-In under this Section&nbsp;2(d)(iv)&nbsp;is subject to delivery by the Holder of the aggregate Exercise Price in accordance with
the terms of Section&nbsp;2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination
and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other
than to the extent that information on the number of outstanding shares of Common Stock of the Company is provided by the Company and
relied upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder and the Company shall have
no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that
are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section&nbsp;2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%] of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the
same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Company, at 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: <B>James Hayward</B>, email address: james.hayward@adnas.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this
Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on a day that is not a Trading
Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is
required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on
Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>applied dna sciences, inc.</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 47%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Name:</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">applied
dna sciences, inc.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 17%">Name of Investing Entity:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 73%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing
    Entity:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 55%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Phone Number:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Email Address: </TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 35%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>tm2222857d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of ________, 2022, between Applied DNA Sciences,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each, including its successors
and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&nbsp;IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&nbsp;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second
(2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means McDermott Will&nbsp;&amp; Emery LLP, with offices located at One Vanderbilt Avenue, New York, NY 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day immediately
following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if this Agreement
is signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later than 9:01 a.m.&nbsp;(New
York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman&nbsp;&amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;Common Stock, options or other equity awards to employees, officers, consultants,
members of its strategic advisory board, or directors of the Company pursuant to any stock or option plan or employee stock purchase
plan duly adopted for such purpose (provided that issuances to consultants and members of its strategic advisory board shall be unregistered
and carry no registration rights other than on a registration statement on Form&nbsp;S-8 and shall not exceed an aggregate of 20,000
shares (subject to adjustment for any stock splits or recapitalizations following date hereof) in any three (3)&nbsp;month period), by
a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;up to $_______ of Securities
issued to other purchasers pursuant to the Prospectus concurrently with the Closing at the Per Share Purchase Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
of the Company, in the form of <U>Exhibit&nbsp;C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Medical
Device</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $_____, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per
Pre-Funded Warrant shall be the Per Share Purchase Price minus $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright&nbsp;&amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section&nbsp;2.2(a)&nbsp;hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised
in full, substantially in the form of <U>Exhibit&nbsp;B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any
amendment thereto, or filed with the Commission pursuant to Rule&nbsp;424(a)&nbsp;of the rules&nbsp;and regulations of the Commission
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i)&nbsp;the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to [___ a.m.] (New York City time) on the date hereof and (ii)&nbsp;any free writing prospectus (as defined in the
Securities Act) identified on <U>Schedule A</U> hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission (File No.&nbsp;333-266223) which registers the sale of
the Shares, the Warrants and the Warrant Shares to the Purchasers, and includes any Rule&nbsp;462(b)&nbsp;Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was filed with
the Commission on or prior to the date hereof and became automatically effective pursuant to Rule&nbsp;462(b)&nbsp;promulgated by the
Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;A
Warrants</U>&rdquo; means, collectively, the Series&nbsp;A Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a)&nbsp;hereof, which Series&nbsp;A Warrants shall be exercisable immediately and have a term of
exercise equal to five (5)&nbsp;years, in the form of Exhibit&nbsp;A-1 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;A
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Series&nbsp;A Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;B
Warrants</U>&rdquo; means, collectively, the Series&nbsp;B Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a)&nbsp;hereof, which Series&nbsp;B Warrants shall be exercisable immediately and have a term of
exercise equal to thirteen (13) months, in the form of Exhibit&nbsp;A-2 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;B
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Series&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreement, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219 and a facsimile number of (718) 765-8782, and any successor transfer agent
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.11(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Series&nbsp;A Warrants, Series&nbsp;B Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Series&nbsp;A Warrant Shares, Series&nbsp;B Warrant Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase,
up to an aggregate of $_______ of Shares, Series&nbsp;A Warrants and Series&nbsp;B Warrants; <U>provided</U>, <U>howeve</U>r, that, to
the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in
excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser
may elect to purchase Pre-Funded Warrants in such manner to result in the same aggregate purchase price being paid by such Purchaser
to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, with respect to each Purchaser, at the election
of such Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of the Securities on the Closing Date. Unless otherwise directed by the Placement Agent, each Purchaser&rsquo;s Subscription Amount as
set forth on the signature page&nbsp;hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and/or Pre-Funded Warrants
(as applicable to such Purchaser) and Series&nbsp;A Warrants and Series&nbsp;B Warrants as determined pursuant to Section&nbsp;2.2(a),
and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction
of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the
Closing documentation. Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus, the Company may
sell up to $_______ of additional Securities to purchasers not party to this Agreement, and will issue to such purchasers such shares
of Common Stock, Series&nbsp;A Warrants and Series&nbsp;B Warrants or Pre-Funded Warrants, Series&nbsp;A Warrants and Series&nbsp;B Warrants
in the same form and at the same Per Share Purchase Price. Unless otherwise directed by the Placement Agent, settlement of the Shares
shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue
the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)&nbsp;at
the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver
such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer
to the Company). Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise (as defined in the Pre-Funded Warrants)
delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Closing Date, which may be delivered at any time after the time
of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New
York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants)
for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
legal opinion of Company Counsel, in a form reasonably acceptable to the Placement Agent and the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">subject
to the penultimate sentence of Section&nbsp;2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">subject
to the penultimate sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company&rsquo;s Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common
Stock issuable upon exercise of such Purchaser&rsquo;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Series&nbsp;A Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of
such Purchaser&rsquo;s Shares plus Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants, if applicable,
with an exercise price equal to $_____, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Series&nbsp;B Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of
such Purchaser&rsquo;s Shares plus Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants, if applicable,
with an exercise price equal to $_____, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">as
to each Purchaser purchasing Pre-Funded Warrants, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to a Pre-Funded Warrant divided
by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">on
the date hereof, the duly executed Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ix)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific
date therein in which case they shall be accurate in all material respects as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are as set forth in the SEC Reports. Except as set forth in the SEC Reports,
the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and
free of preemptive and similar rights to subscribe for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing (if applicable in such jurisdiction) under the laws of the jurisdiction of its incorporation or organization, with
the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither
the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
could not have or reasonably be expected to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii)&nbsp;a material adverse effect on the results of operations, assets, business, prospects or condition
(financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&rsquo;s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or
(iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting
or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings
required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus, (iii)&nbsp;application(s)&nbsp;to
each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby,
and (iv)&nbsp;such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of
shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, which became effective on&nbsp;_______, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;),
including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Preliminary Prospectus or the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required
by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule&nbsp;424(b). At the
time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the
Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Pricing Prospectus and the Prospectus and any amendments
or supplements thereto, at the time the Pricing Prospectus or the Prospectus, as applicable, or any amendment or supplement thereto was
issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did
not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U>&nbsp;shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company&rsquo;s stock option plans or vesting of restricted stock units, the issuance
of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or
exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No
Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). Except as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of
any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus
and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have
been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except
that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial
position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i)&nbsp;there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities
(contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities to any
officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the
Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement
or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence or development has occurred or exists
or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the
date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)&nbsp;adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters that would reasonably be expected to have a Material Adverse Effect. The Company and its
Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment
practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company
or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not
such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other
governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>. The Company and its Subsidiaries (i)&nbsp;are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)&nbsp;and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulatory
Permits</U>. Except as set forth on <U>Schedule 3.1(n)</U>, the Company and the Subsidiaries possess all certificates, authorizations
and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses
as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material
Adverse Effect (&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings
relating to the revocation of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)&nbsp;Liens for the
payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment
of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this
Agreement, except where such action would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary
has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim
or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could
not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company
and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage in an amount as set forth on <U>Schedule 3.1(q)</U>. Neither the Company nor any
Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transactions
With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services or separation from service as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to
or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any
such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess
of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses
incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements, restricted stock award agreements
and restricted stock unit award agreements under any equity plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed
in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company
and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e))
for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed
by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in
the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that
have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Fees</U>. Except as set forth in the Pricing Prospectus or the Prospectus, including compensation paid to the Placement Agent in connection
with the placement of the Securities, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any
Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section&nbsp;that may be due in connection
with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue
to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer
through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to
the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Pricing Prospectus
or the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company
and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this
Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press
releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges
and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section&nbsp;3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof,
and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of
its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its
liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any liabilities for borrowed money or amounts owed in
excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y)&nbsp;all guaranties, endorsements
and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z)&nbsp;the present value of any lease payments in excess of $100,000
due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect
to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and
all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is Marcum LLP. To the knowledge and belief of the Company, such accounting
firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect
to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending September&nbsp;30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may
engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during
the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z)&nbsp;such hedging
activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the
hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid to the Placement Agent in connection
with the placement of the Securities and compensation paid to underwriters and/or placement agents in connection with prior offerings
of the Company&rsquo;s securities, in each case as set forth in the SEC Reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>FDA</U>.
Other than as previously disclosed within the SEC Reports, as to each product subject to the jurisdiction of the U.S. Food and Drug Administration
(&ldquo;<U>FDA</U>&rdquo;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;)
that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such
product, a &ldquo;<U>Medical Device</U>&rdquo;), such Medical Device is being manufactured, packaged, labeled, tested, distributed, sold
and/or marketed by the Company in compliance with all applicable requirements under Section&nbsp;564 of the FDCA for Emergency Use Authorization
(<U>EUA</U>), and the conditions of authorization of the EUA authorizing the sale of any Company product, except where compliance has
been waived by the FDA or the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or,
to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)&nbsp;withdraws
any EUA relating to any Medical Device, (ii)&nbsp;imposes a clinical hold on any clinical investigation by the Company or any of its
Subsidiaries, (iii)&nbsp;enjoins production at any facility of the Company or any of its Subsidiaries, (iv)&nbsp;enters or proposes to
enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (v)&nbsp;otherwise alleges any violation
of any laws, rules&nbsp;or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all
material respects in accordance with all applicable laws, rules&nbsp;and regulations of the FDA applicable to the manufacture, packing,
labeling, testing, distribution, sale and/or marketing of any Medical Device under EUA. Except as set forth in the SEC Reports, the Company
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cybersecurity</U>.&nbsp;
(i)(x)&nbsp;There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company
and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)&nbsp;in accordance
with the terms of the Company&rsquo;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair market value
of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7),
(a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto including the Disclosure Schedules) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask
such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to
evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser
with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the
Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement
Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be
provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its
Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company, the Placement Agent, or any other Person representing the Company setting forth
the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with
respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered
by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without
limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).
Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or
preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the
representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document
or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions
contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the
issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to
any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent
registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale
or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement
is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available
for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company
to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company
shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of
the Warrant Shares effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>. Until the earlier of the time that (i)&nbsp;no Purchaser owns Securities or (ii)&nbsp;the Warrants have expired,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the
reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules&nbsp;and
regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless
shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including the Transaction Documents as
exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any
of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, or agents, including
in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press
release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees or Affiliates, on the
one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall
consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company
nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company (other than the press release described in the first sentence of this Section&nbsp;4.4), which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication, or if such disclosure is consistent with the Form&nbsp;8-K. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing
with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as
required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b)&nbsp;to the
extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Non-Public
Information</U>. Except with respect to the material pricing terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such
information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any
of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents,
employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to
applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale of
the Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of
the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b)&nbsp;for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation
or (d)&nbsp;in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a)&nbsp;any material breach of any of the representations, warranties, covenants or agreements made
by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties
in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser
Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material
breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or
understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal
securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or
willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume
the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Purchaser Party except to the extent that (x)&nbsp;the employment thereof has been specifically authorized
by the Company in writing, (y)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (z)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable, actual and
documented fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this
Agreement (1)&nbsp;for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The indemnification required by this Section&nbsp;4.8 shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred; provided,
however, that if it is subsequently determined by a final, non-appealable judgment of a court of competent jurisdiction that a Purchaser
Party was not entitled to receive such periodic payments, such Purchaser Party shall promptly (but in no event later than five Business
Days) return such payments to the Company. The indemnity agreements contained herein shall be in addition to any cause of action or similar
right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
of Common Stock</U>. The Company hereby agrees to use commercially reasonable best efforts to maintain the listing or quotation of the
Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list
or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant
Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading
Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary
to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company
will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply
in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market.
The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another
established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other
established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)&nbsp;file
any registration statement or amendment or supplement thereto; provided, however, that this Section&nbsp;4.11(a)&nbsp;shall not prohibit
(a)&nbsp;the filing of the Prospectus or the filing of a registration statement or any amendment or supplement thereto pursuant to the
Registration Rights Agreement, dated October&nbsp;7, 2020, by and between the Company and Dillon Hill Capital, LLC or pursuant to the
Registration Rights Agreement, dated October&nbsp;7, 2020, by and between the Company and Dillon Hill Investment Company, LLC, (b)&nbsp;the
filing of any Annual Report on Form&nbsp;10-K, Quarterly Report on Form&nbsp;10-Q or Current Report on Form&nbsp;8-K that may be deemed
to be an amendment or supplement to any existing registration statement or (c)&nbsp;the filing of any amendment or supplement to any
existing registration statement solely for the purpose of revising any required disclosure in such registration statement and not for
the purpose of increasing the offering size pursuant to any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until the one-year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or
effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;,
whereby the Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that after the 120<SUP>th</SUP>
day following the Closing Date, the Company&rsquo;s issuance of shares of Common Stock or Common Stock equivalents pursuant to an at-the-market
offering facility shall not be deemed a Variable Rate Transaction hereunder. Any Purchaser shall be entitled to obtain injunctive relief
against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section&nbsp;4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement shall be offered or paid to any Person to
amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all
of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by
the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section&nbsp;4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information
included in the Disclosure Schedules.&nbsp; Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to
the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant
hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4, (ii)&nbsp;no Purchaser
shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities
laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade
in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp;
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply
with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise
the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party
to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific
performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&nbsp;
This Agreement may be terminated (a)&nbsp;by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties or (b)&nbsp;by the
Company by written notice to the Purchasers, if in either case the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>)
Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination will affect the right of any party to
sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and the Prospectus,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York
City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day
or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased (or, if prior to the Closing, all of the Purchasers) at least
50.1% in interest of the Shares and Pre-Funded Warrants based on the initial Subscription Amounts hereunder or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser
(or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding
upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the
Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section&nbsp;4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at
law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U></FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If the last or appointed day for
the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may
be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.21</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY UNDER THE TRANSACTION
DOCUMENTS, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-transform: capitalize"><FONT STYLE="text-transform: uppercase"><B>applied dna sciences, inc.</B></FONT></TD><TD STYLE="text-align: justify"><U>Address for Notice:</U></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: left; width: 47%">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Applied DNA Sciences,&nbsp;Inc.</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="text-align: justify">50 Health Sciences Drive,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Title:</TD><TD STYLE="text-align: justify">Stony Brook, New York 11790</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Attention: James Hayward</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">With a copy to (which shall not constitute notice):</TD><TD STYLE="text-align: justify">Email: james.hayward@adnas.com</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">McDermott Will&nbsp;&amp; Emery LLP</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">One Vanderbilt Avenue</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">New York, New York 10017</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">Attention:</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">Email:</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">APDN
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%">Name of Purchaser:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 75%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Purchaser</I>:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 55%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 25%">Email Address of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 65%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Series&nbsp;A Warrants: _________________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">&#168;</FONT>4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Series&nbsp;B Warrants: _________________ Beneficial Ownership
Blocker <FONT STYLE="font-family: Wingdings">&#168;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrants: _________________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">&#168;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>tm2222857d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: #FEFEFE"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B><IMG SRC="tm2222857d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B>Applied
DNA Announces Pricing of $12 Million Upsized Public Offering, <BR>
Priced at a Premium to Market Under Nasdaq Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STONY BROOK, N.Y., - August
4, 2022</B> <FONT STYLE="font-weight: normal">- Applied DNA Sciences, Inc., (NASDAQ: APDN) (the &ldquo;Company&rdquo; or &ldquo;Applied
DNA&rdquo;), a leader in polymerase chain reaction (&quot;PCR&quot;)-based technologies, today announced the pricing of a public offering
of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase up
to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined offering
price to the public of $4.00 per share (or common stock equivalent) and associated warrants, priced at a premium to market under Nasdaq
rules. The Series A warrants will have an exercise price of $4.00 per share, are exercisable immediately upon issuance, and will expire
five years following the date of issuance. The Series B warrants will have an exercise price of $4.00 per share, are exercisable immediately
upon issuance, and will expire thirteen months following the date of issuance. The closing of the offering is expected to occur on or
about August 8, 2022, subject to the satisfaction of customary closing conditions. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
gross proceeds to the Company from the offering are expected to be $12 million, before deducting the placement agent&rsquo;s fees and
other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for further development
of the Company&rsquo;s Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes, which may include research
and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of
or investments in businesses, products and technologies that complement our business, although the Company has no present commitments
or agreements to make any such acquisitions or investments </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The securities
described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-266223) previously filed with the Securities
and Exchange Commission (SEC) which became effective on August 4, 2022 and an additional registration statement filed pursuant to Rule
462(b) which became automatically effective on August 4, 2022. The offering is being made only by means of a prospectus, which is part
of the effective registration statements. When available, electronic copies of the final prospectus may be obtained for free on the SEC&rsquo;s
website located at&nbsp;<U>http://www.sec.gov</U> and may also be obtained by contacting </FONT>H.C. Wainwright &amp; Co., LLC at 430
Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at <U>placements@hcwco.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This press
release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA Sciences is a
biotechnology company developing technologies to produce and detect deoxyribonucleic acid (&quot;DNA&quot;). Using PCR to enable both
the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based
therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for
industrial supply chain security services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visit&nbsp;</FONT><U>adnas.com</U>&nbsp;for
more information. Follow us on&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>LinkedIn</U>. Join our&nbsp;<U>mailing list</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company&rsquo;s common
stock is listed on NASDAQ under the ticker symbol &lsquo;APDN,&rsquo; and its publicly traded warrants are listed on OTC under the ticker
symbol &lsquo;APPDW.&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements made by Applied
DNA in this press release may be &quot;forward-looking&quot; in nature within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks
and uncertainties, many of which are beyond the control of Applied DNA. Forward-looking statements include statements relating to the
offering, including the completion of the offering, the satisfaction of customary closing conditions related to the offering, the expected
proceeds from the offering and the intended use of net proceeds therefrom, the timing of the closing of the offering and the potential
exercise of the warrants. Actual results could differ materially from those projected due to its history of net losses, limited financial
resources, limited market acceptance, the possibility that Applied DNA&rsquo;s testing services could become obsolete or have their utility
diminished and the unknown amount of revenues and profits that will results from Applied DNA's testing services. Further, the uncertainties
inherent in research and development, future data and analysis, including whether any of Applied DNA's current or future diagnostic candidates
will advance further in the research and/or validation process or receiving authorization, clearance or approval from the FDA, equivalent
foreign regulatory agencies and/or the New York State Department of Health (&ldquo;NYSDOH&rdquo;), and whether and when, if at all, they
will receive final authorization, clearance or approval from the FDA, equivalent foreign regulatory agencies and/or NYSDOH, the unknown
outcome of any applications or requests to FDA, equivalent foreign regulatory agencies and/or the NYSDOH, disruptions in the supply of
raw materials and supplies, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including our
Annual Report on Form 10-K filed on December 9, 2021, its Quarterly Report on Form 10-Qs filed on February 10, 2022 and May 12, 2022 and
other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events,
unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investor Relations Contact: </B></FONT>Sanjay
M. Hurry, 917-733-5573, <U>sanjay.hurry@adnas.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Web:</B></FONT> www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Twitter: </B></FONT>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>tm2222857d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 99.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2222857d1_ex99-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: #FEFEFE"><B>Applied DNA
Announces Closing of Upsized $12 Million Public Offering</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STONY BROOK, N.Y., - August 8, 2022</B>
<FONT STYLE="font-weight: normal">- Applied DNA Sciences, Inc., (NASDAQ: APDN) (the &ldquo;Company&rdquo; or &ldquo;Applied DNA&rdquo;),
a leader in polymerase chain reaction (&quot;PCR&quot;)-based technologies, today announced the closing of its previously announced public
offering of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase
up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined
offering price to the public of $4.00 per share (or common stock equivalent) and associated warrants, priced at a premium to market under
Nasdaq rules. The gross proceeds to the Company from the offering were $12 million before deducting the placement agent&rsquo;s fees
and other offering expenses payable by the Company.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The Series
A warrants have an exercise price of $4.00 per share, are exercisable immediately upon issuance, and expire five years following the
date of issuance. The Series B warrants have an exercise price of $4.00 per share, are exercisable immediately upon issuance and expire
thirteen months following the date of issuance. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">H.C. Wainwright
 &amp; Co. acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The offering
was conducted pursuant to the Company&rsquo;s registration statement on Form S-1 (File No. 333-266223) previously filed with the Securities
and Exchange Commission (SEC), which became effective on August 4, 2022, and an additional registration statement filed pursuant to Rule
462(b) which became automatically effective on August 4, 2022. The offering was made only by means of a prospectus, which is part of
the effective registration statements. Electronic copies of the final prospectus may be obtained for free on the SEC&rsquo;s website
located at&nbsp;<U>http://www.sec.gov</U> and may also be obtained by contacting </FONT>H.C. Wainwright &amp; Co., LLC at 430 Park Avenue,
3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at <U>placements@hcwco.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This press
release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA Sciences is a biotechnology company
developing technologies to produce and detect deoxyribonucleic acid (&quot;DNA&quot;). Using PCR to enable both the production and detection
of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the
detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain
security services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visit&nbsp;</FONT><U>adnas.com</U>&nbsp;for
more information. Follow us on&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>LinkedIn</U>. Join our<U>&nbsp;mailing list</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company&rsquo;s common stock is listed
on NASDAQ under the ticker symbol &lsquo;APDN,&rsquo; and its publicly traded warrants are listed on OTC under the ticker symbol &lsquo;APPDW.&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The statements made by Applied DNA in this
press release may be &quot;forward-looking&quot; in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe
Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and
uncertainties, many of which are beyond the control of Applied DNA. Forward-looking statements include statements relating to the offering,
including the intended use of net proceeds therefrom and the potential exercise of the warrants. Actual results could differ materially
from those projected due to its history of net losses, limited financial resources, limited market acceptance, the possibility that Applied
DNA&rsquo;s testing services could become obsolete or have their utility diminished and the unknown amount of revenues and profits that
will results from Applied DNA's testing services. Further, the uncertainties inherent in research and development, future data and analysis,
including whether any of Applied DNA's current or future diagnostic candidates will advance further in the research and/or validation
process or receiving authorization, clearance or approval from the FDA, equivalent foreign regulatory agencies and/or the New York State
Department of Health (&ldquo;NYSDOH&rdquo;), and whether and when, if at all, they will receive final authorization, clearance or approval
from the FDA, equivalent foreign regulatory agencies and/or NYSDOH, the unknown outcome of any applications or requests to FDA, equivalent
foreign regulatory agencies and/or the NYSDOH, disruptions in the supply of raw materials and supplies, the fact that there has never
been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 9, 2021, our Quarterly
Report on Form 10-Qs filed on February 10, 2022 and May 12, 2022, and other reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investor Relations Contact: </B></FONT>Sanjay
M. Hurry, 917-733-5573, <U>sanjay.hurry@adnas.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Web:</B></FONT> www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Twitter: </B></FONT>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>apdn-20220804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiGybOdzZR+yYkxtmB4bbm6fy8inJmCOi4//IBm4Y8D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:apdn="http://adnas.com/20220804" elementFormDefault="qualified" targetNamespace="http://adnas.com/20220804">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://adnas.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="apdn-20220804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="apdn-20220804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apdn-20220804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apdn-20220804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://adnas.com/role/Cover" xlink:href="apdn-20220804.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://adnas.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2222857d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2222857d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Q N\# 2(  A$! Q$!_\0
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MBB@ HHI"X!H 6BFB0$]:=0 44$XI X)ZT +1397\M":2-]^* 'T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU4S]W\:U64X?JOQ,GF>)MN>J-^TU /\ F%3?]_A_A4;?M00+_P PF;_O^/\
M"O)7[U!)UK6.3X7^7\68RS;$K:7Y'K<G[55NA_Y!$_\ W_'^%1']K2V"_P#(
M'G_[_C_"O'9CDFJDO"GZUJLEPG6/XLS>;XO^;\$>T/\ M?6R_P#,'N/^_P"O
M^%1/^V/:QG_D"W!_[>%_PKQ*7O52ZZUJLCP;^S^+,WG6,7VOP1[I)^VA:H?^
M0'<?^!"_X5$W[;-H!_R KC_P(7_"O![CA:I2=ZVCP_@GO'\68O/<8OM?@CZ
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M #3;6#_W%8O_ (W44G_!P_H4?_---9_\&L7_ ,;K\OY?Z55N>16W_$,N'_\
MGR__  *?_P D1_Q$?/O^?W_DD?\ (_49_P#@XGT%/^:9ZQ_X-H__ (W4+_\
M!QEH*G_DF.L?^#:/_P"-U^6TWW*I2_>-:KPOX=?_ "Y?_@<_\S!^).?_ //[
M_P DC_D?JE)_P<=: G_-,=9_\&T?_P ;KZF_X)\_\%"]#_;]\,>(;S3-&O\
M0;WPU/#%>6ES(LH"S"0QLK@#.?+?(QQBOY_KCI7ZD_\ !MI_R"_C%_UVT?\
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M^!/V=/A:O@SP=X<T_1O#F&\RTCC!6X+C#M(3]\L.#GM7?T4;:H-]SY\\(_\
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M.WYUA_$K_@CY^SY\6OC!)XWUKP%93:S<SBYNTCD:.VO90<[Y(EX8YYKZ;HH
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M<\Y8C/<5Z.'S;&4(<E&HTNQPU\KP=>7/7IIL_/O]C;_@GM\4?^"NOQFM=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2222857d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2222857d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Q O4# 2(  A$! Q$!_\0
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M/Q^_:*\&?LQ?#N\\4>.=?L?#VBVBDF>X?!D;!PD:CYG<XX"@G\ :_'7]N/\
MX.:_$OC>XOO#OP3TH>&M-D)A'B#4E$E](,XWQQ\I%WZ[B.""*!I7/V7^*7QQ
M\'_!#06U3QAXET3PUIZ@GS]2O([=6QV7<1N/L,FL[]G[]IKP)^U1X+E\0_#[
MQ)8^)]&@NWL9;FU#@1S)@LC!P&!PRGD<A@1Q7XS?LP?\$;O$?_!0/36^(WQ7
M^/,/BE9H3=S6.B:G_:FHLOW@CNY(C;C&TIWX-?J!_P $O?V>?!/[-/[.KZ!X
M%T&_T*PEU26ZN_MEVUU/>3E(U,K.0.JH@P!@;>@Z4"/I2BBB@ HHHH ****
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M>: .>U3X_GP]\9=&\*ZEH5[9P>(KR73],OWN83]IGCM9KIOW08N(_+@EP_\
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M[V!4=M^S3\(KSX)?#*/0[RYM9V6[N;F**T1TM;&.69I$MH59F98XPP4#/;C
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MG_D5_#7_ 'U-_P#%5$__  6@\;I_S*WAG_OJ;_XJOC^XZU6GZ"MX<&9+_P!
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MOB.AX\$>#?\ ONX_^+KX&;@&J<_6MEX?<//_ )AE]\O\S&7'6?\ _01+\/\
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M1V. =I],U]NP_ KP=;?#*7P9%X:T>'PI-";>32H[94M7C/52@X.>]=6%Q2T
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MXTT_LI>!"?\ D VW_?3?XUZ-13_M#%?\_)?>Q?V?A?\ GVON1YNW[)O@,_\
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MP8/_ #)5A_WV_P#C7O6P4;!1_;F8_P#/^?\ X%+_ #%_8>7?\^(?^ H\#/\
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139842962276768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Applied DNA Sciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000744452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">59-2262718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">50 Health Sciences Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stony Brook<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">240-8800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tm2222857d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apdn-20220804.xsd" xlink:type="simple"/>
    <context id="From2022-08-04to2022-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-08-04to2022-08-04">0000744452</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-08-04to2022-08-04">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-08-04to2022-08-04">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-08-04to2022-08-04">2022-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-08-04to2022-08-04">Applied DNA Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-08-04to2022-08-04">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-08-04to2022-08-04">001-36745</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-08-04to2022-08-04">59-2262718</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-08-04to2022-08-04">50 Health Sciences Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-08-04to2022-08-04">Stony Brook</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-08-04to2022-08-04">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-08-04to2022-08-04">11790</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-08-04to2022-08-04">631</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-08-04to2022-08-04">240-8800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-08-04to2022-08-04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-08-04to2022-08-04">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-08-04to2022-08-04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-08-04to2022-08-04">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-08-04to2022-08-04">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="From2022-08-04to2022-08-04">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-08-04to2022-08-04">APDN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-08-04to2022-08-04">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M ?8"^'XEI7D;V&UK]:O#^#]02P,$%     @ YZX(59^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .>N"%5=&>2;200  ($0   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #GK@A5GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( .>N"%67BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .>N"%6JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #GK@A5)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #GK@A599!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2222857d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adnas.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2222857d1_8k.htm">tm2222857d1_8k.htm</File>
    <File>apdn-20220804.xsd</File>
    <File>apdn-20220804_lab.xml</File>
    <File>apdn-20220804_pre.xml</File>
    <File>tm2222857d1_ex10-1.htm</File>
    <File>tm2222857d1_ex4-1.htm</File>
    <File>tm2222857d1_ex4-2.htm</File>
    <File>tm2222857d1_ex4-3.htm</File>
    <File>tm2222857d1_ex99-1.htm</File>
    <File>tm2222857d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2222857d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2222857d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apdn-20220804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apdn-20220804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "apdn-20220804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "apdn",
   "nsuri": "http://adnas.com/20220804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2222857d1_8k.htm",
      "contextRef": "From2022-08-04to2022-08-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://adnas.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2222857d1_8k.htm",
      "contextRef": "From2022-08-04to2022-08-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://adnas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-22-087502-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-087502-xbrl.zip
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ML2WK**)%ZQH2T*X.BB$,"A;('0A,&:"X*4*\0_-/@ODP9!I*/\ 85NVXU+(
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M%$,9!$R]]N!WJ-012(5X(.=6L,R;YWB%D7E.-N!,BOX05Q0--:]8ZM,'0=1
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M\,T2H#@T1JAO1@)CJ C51?M$UZT]X-["6YQQO]R;9NV1_P%02P,$%     @
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MY+TF"O4M[7'RKL:^G+S_T%BI:^E()PB/%A 88MP$LV[9;"RH!)F,:;(9")%
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MRL5RN<*FW&%WW/37MPT\3@CNY_QCB!6X(TH6I2BNH=09'T^:C9TOM\]1DTL
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M>V[@[EP=B'M\Y>ZB:LZ':F?@YW@J@K7<OP^61,(7_G[I>$31$,SFPN*NP ;
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M^$3V6)/)FM'1W#P]LVQ1L_&(W"MQ;'%B^%"9H0L-GV[\\<*SUYKAV>.;D^&
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M,LF#7= >[#^(=:'Q>]7?+V"]<&!42Z3G6WCIL+EWJ%U#&FQG2:I!>9(A*I,
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M36L_9[KER*(["7%%1P7&]QS<.Z_!A,+(%I:9L>)W<1<X-Q&8A39]VA&:FV^
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M>K*SA8N:;7L/-$.XS9HQ X$LB=2 N%XAF]ZQ23W\ FD3N,1=YS?=EML'=XV
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MHB2UM\O$N!!9XOJ#:(TI5>F[^Z%NY\I[,$+7,Z9]6+<.FZ*-"L&)7+XIG5H
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M-^J\I(LHA&-M&/MA,*E;=8QBN+;VFGV8*?^L8"VLO!,?3FM++[A69.=)3W4
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M3%K;3Y#>DX]( F-*P3.$YUW,>G$%;%DA5#=A#ZX(9R!S8M,F4+"&IEJ=8>!
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M"-(G]<C>\-2"R.B'5,.*1Y4IB!-B($YY;D4]#W+_1;A;J<83]"RW?[ )5\=
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MZ%*ZDBO['85$!D>'ZS2;.NJ,%8KTBJE!"+.%IH.B@"[7&*2AX][U?P[R!O8
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MJ:S.LLIX5!?<.UR5U87@KK+*N@NY0K.P_/0<\%*YA0H_+FF 7$8N*#J%B"(
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MH(6.8K[7/@Q$!>%I8WLAK:#!+<"6LA*XP^PJFT%)#T(,Q.)S Q:-R1FDBX;
MTA[=*S-U_?)(_;G9P<;:5 'G&QRP)7LXQP?YM1#BTFG,<.%5M-^OV5U["5!+
M@/!V>NMR]DS91$7$5RE1PV6D= M6=8BH?8Z;4D[]2H2!$@<J5O8F\<)ATCNR
MJP YXRQ,EPP9^<X0B&4=8@T?KU^O$+<$#+!$;7P7HH4O8#0A@%-U*BCL1'<[
M(X/A.H-KCXGKV?E/S*F#A@^'LRW5G6W+;M!F/-VEA]-Q*!\/& ?M?(KWO8><
METCK[FPTYA KWMM3R'6&18C(&:8Z<D_FNPO8YB"Y@UXB]EV"_NZ.T5&-A51$
MF$]@M3)0/P--/S-\^6_9WHISNR9VW(F. R$WXL@29^<6$U?M4@GZ1*OV"F2G
M05I9*K&+GR67M&*,^>4]BS&_?(@Q;]Q5L_;JM#YRT9'R&=\V;'9#Z6'#!]$P
MZ0Z"4H@CJQY4%D,T=L(:TC?J0Z<$D,93T9SW$PP:&8_Y,HW1_YHG;-&3)CP%
MFX$XCD$/A:,Y<.:^)LR#8T\U6$,]/5N(G@K7Z7AN_HGOI/O.J@W(U4?ZTLP$
M*NB/1D#8&7(;N4>A57ZL"5;3P^:6(&.9;"67I6,U_#A../R'T2-$UDTPT(=W
M,&D&0/Q@>!%';-GA'8 .^1G4UA3T OL7,SB 30K9H2R'U6PEJEX.$'VK70_F
MHN450'Q513R;TZ/HM@?*6 NKDAA@4K[[K#J!^87Q)].Y64YH3%BKQZT#XF^^
MU0J0D*?/X2L.C=8,@FX0NMPVO;)6 UZJVUO>6MW\F_$NCZZU%]+UHGQ(>#?:
MI, I,\K"*Q"5@KB#X%^74#:6BFA]"L<GNO+=DM20O8AZ[7YD8<>#VUP3;VZ@
MC8R%\SZ,S3&_A!0U:9#.(E?#3D.BA$YG3K6 R@4J[V""%Q6F&*42563A2*JG
MY?@![4T=Y8!^<]Q6*&(*/BB=4AL$3,JX"M@R&<P*T(=P#!9F! ,K\#:0M,)@
MJSG]H,W(<$B<ABG]%^$O]<7\5EJ,^"XGT24</O09/48R;HA!-@8SZ9= XP%4
M)9-JG&6,,4<4:LL%QJGI?0EHLFK-?@7WFZD%2A!H#U I2&.ZTA019(U:@2YW
M,&,WSSC"6:^\H$*^2J4+YP622>7BXWI)8GY-A3="3NGP_!P21H6"B9(@B=":
MZR5HH\&YQ5RS:HPYE45P=#GWGXTCAD-"9^IGZ3J$)=\7KB1=_"TDD#0W$#ZQ
MB70.FTCD=XB=I- N!NMX/$W#(UXD]XM#8?U,:STW.SA?+A1%ISS;K'K"+&<9
MX6_=])7*WXVI,C4^]H0,M4F:%U!R;TZ-A&K_S"/2!9]X?M4,>-PLO$G:SVS*
MPB_Q%K%*/11_/Z.8/!Y\*4%W\;@;PC*<3&@32![B2>DXX38"&QEK+YE[*9HC
M@KWR>'P(JC2%06)6Q])Q(7T;Y'K!ID@-%@#W))>AA*-STX!\' Y17=C?XBX<
M;(:0 NKCPH[@G$W#@3OI$H):W-! ONHH015GYHJ#FQPR)*I&8";I!FLQ(ZH_
M&SVE, I%OE5.;VA6O]DP&43ES<61&.=G!Q)NZ9"4!5PXO"R+I(^)^QH/77MU
M4P^23+$MWVW[61H*#VH]'U?N %X=H46]ZESDZ+/"$Y1PTASW4,<H,3]6Y6&2
ME1J>P[*YA3P])84ACTS,(S1QFN;UK'NX92S>%UQL=D_2)"I@!7/[@'%W(;#P
M<&3L!=A+Z',G>:@.G05N4(^NA?:-)(.9-,C\2QN%)8;S)<WU\MS<6J[9D13C
MTMPVV@AU0Z23U"I22BD*@H=0.%=4ER Z#! 5<AO5>-RO?;KV,H@34J0'G9(B
M:$(R@6&*U1)9O6&8Q=X)VF?R8V[QW-;Z7*F.%A;Z]I;RKL@ISY60(=S\#DM>
M6%1)@R]KS%%4V\, E1DE.AW[GX<(R92AGQ$(!7T/N=M#M&"E-@Q!/2I65 J1
MC+-P#@0DW!!SKT<9T:4W,) 5PC@WY,ABFGH4D3E/,^:TQE9DOAN!7L48:Q[A
MVVBU:U$99^%6_*_ 7,YY$=%;(]$E*L,>Q4M-\'C5MC>Q<EO76A$OG87)EVP^
M*X9\)!/ R#Q<\$7XVR$Y._!442A$QXFL,!C@(1M*Z*46WO)3IPE*)%KW UUW
ME8C)_$F3O =.%VL*T3"2500 $>6O76+A)L-5H'"03DX76539&#,Y+ATCJ^XB
M'#E&.F0>%Q^JM-;,(DC'8_MY%F4<;?Y9MV)>YI=[EI?YY2$OLW%7Z=IKR-JF
M@;,(6[F]U:%<K%<D+2"?KK+1X$3!T*<J#RC!ETKEH^Z(KKU'\:(BM2*R[*Q8
MD9(JJE;GEDIK&VSZU0>V\AG@#DAXV(+'K.B]-@,SPD*Y7[F(ZXUMN*&GUV#=
MTLS'J]5]O2&CPS</8RS*1*S.>'&HXD(XVVHP=0K&5RJ>"',&* .B^"*>H2:M
M.+"4G@EYH@#N(/7IMA-?((D$RP%\E 5QC0@\ 6!$\^F,[\0:@;S,FZH;M.ZJ
M"APE.][:5#>HV2QUD'QYK7J%U]AMIPF5<!22T!.XH+(&JQ21GJ&"<4NN+<]B
MHH*<UY7K@CDUMX4JE>6SO:7R E@D4/C5O4D$<$EP\L:^?>4$9-  @8DF'<(P
MT;S^%GB(J]"A#6TTE@4;C4]=&D2@PT7#PZ+*:!I@D-*KQ"G,$,*?*40ES _6
MCSFBM5SC344/*"<)]AAXHK2)1],XB?,BH[QFM6ZZIA*^!-&79F'B< C0F82V
ME9  ^<0V)"1T@;AT,R+O^V9MO>^[](D="PWXUAL#]E0R46)<+ SI5VCYC*4P
MTIBQH(7*80J,7.@@@P_G(>9Q>%]]58,<G]Z@E02[$C$OR6H&.;#0)SB#GXU]
M3 T;F8V;<B%*3><EZ^NX;!5>RR*6N9:6$&!:'72I>!K5SFA<6.T&0KGW);33
MH;Z)( ,U6314]Y=S5:NI98EF*L$H?9?._M!X).?E0=EX$_PN;:2U%T@>QV:M
MCDA,[HBB8!7)A%J6\\*%C#&R!GZE?98$U!PC8,@T/T2*=D/ #F%X'EM,%=RG
M%YH[\)UT XD[(C0D0;_\FE8Z?+<T$TX[X!:,$DK%)77R9.%0!6)4N!W]20QK
M^\J/A!^U90PK#AE%'49S<G;-F)/0G5."([IUS'_\#![K76Z7NZAMO!G>!9[#
M*%Q C5K?K%SX*?@ #B_\1 ^)BN$N[!MIS]]>?]-;VZP6$N9D"<YF8(;B(D$[
MAH5%PB^*0CNT%004J)G%+B7LZDCTW22Q>P_ )='OX&!NK#*H-$$&1 =5X/=,
M@5WQ+&(K78PA>HD#5V, SQ* (>4DUA&3#:5?<:\6[HNU%SL<JAI;5?!0DQ11
M*1I4SGQ&*\HO!O>L0C)5.5('(31 .,^ L&J>Q$2>!1]AM8CE.8^&S;DR1#$!
M'W429/,)XZ>IB-91Q4M44@0=&(\>3L_B\SES.&61C=0:PP4#BER>BLF/+!P7
MML!(%$QY$W!MJ4W7W*8 F9T-RUYEF<411"\.!EO@Z$-ALHQ#TUA"EA(Z@R A
M5KZJ#JP26\[2:OS!^G(:T3*"Y8M_'J.1BB1<5(2:9E=0P9P3"F8VB9'/F_XY
MBC&A/<H;_'?C!IRQMH:^1@7@Y;FC[N)V#<<IPVBKHI\5MM2_J,SC_CV+Q>X_
MQ&(W[OY9<SG6 5Q!GYKM/UJ][:WNN^ ?I[W/P:#7;AZ3LP'!VD[0['P.FH>#
M=K=C!N"T/6@$W5YPTNL>MEI'[<[[@#]BOMSN'[7Q@\%!KWOZ_L,@./B,?SMI
M]@;FI_?-=J<_P-]T!Q]:/?[]:>?(_&Q^8=[=[/3I7<;OZ1Z>?FQU!OT&_@T^
MVV[U@U;S\$/PST[WDWGW,3S^R+1@8#YGOM0\/OYL/MW%+[SOM9J#EGE?ZU_P
MY^"DU?O8'@Q:1]BJDY/C]F'SX+@5'#<_&<.QU6O!KP_ZW>/300L><]HY[':.
MVO:Y-*3M7J_U1Q>^^7E["U[>^M=)K]7OFZ;@2/:#=UWS">@0#"2\"X:5S="#
MMQM_7"Y13FN_?=*WI5,GCC7Z'5)J[_S7L_8&]VG%*^#7>W8%_/IP!:S["C"'
MY:?VH&,.C. 3G#G==PU=&"+<ZQS7A?"E(TL26*=$X7QN0$BOS"<+5T5"J07?
M00CGQ46:(8L]%4*FI!]OS4 T\L9Q!NS24,$YI/(64"#?_7[[>X ',<@OGC2/
MX%+Y^Z.]1_CO_DGS4/[]E2_EG5/=-[\'5_&HN(!G[3TVJW/0DU=< F9S&$YD
M2LT3:N?XT5MH_%%PV(6&=O[^Z(5M)7Z::!&-NV1V<SB+0?+X/U')#BA_<#Z;
M&?_<3"]>T(@HA0A#$@;Y,&;EX#@9[GJ7R>#H+;1#/[+<4J!25_H!)!ORAJXE
M\W73D6>#WK<, G^-Q_3E8S?+RULWB<:%G89?7JWT';N_^&O[>Z6O03_H# F^
MOCMO#Q9ORJVX_F#WGP8]NT5O'KUM\DP?=9I!7V::;0Z<[KOKVFKS\N@M7A@K
M-7Y_+_@0A9/BPC8].,K,@=/X$<T>0&YTM78;=]<XZ =9FGYI6 :GX/GS5Z_W
M?D3+;[-<"BXM?!/\(X13\$.X@ C!'39;'VMOH00M$$*A%,C%8JI3X;B,2NA3
M[<W.:C/0 B8"\V_HP^X%]>&_0W/<Y;O#=+KADW#GIXXWY!^'1U$V-8=-\"F>
M3-BO"Z?F :TI!*7,;;D!K>PFD;&:(7-T%D^*H(D<61O0+L?'YO;UWA[ G7YX
MT]S>W8#&T ;\IH8\0_OMIS#.Q9_]GU[K8[.-@8?NN^"D^;[E1Q&"X]:[07!P
MW.S\<W/=VOJN]=OO.\W!::]%W7H'T9K3WN&'9M]T]EWW^+C[J?^_F]NI%7WU
M5_?,5W_UX*M_S^/ [1!_^_0AFKBJO]8\.>J 'X5.6;]U>-IK8\A2'AXTW_=:
M+8AI;O#^NX-@!N&CD!5K>^O'1S("&\C8WGJ(9-S&B7^^_YB\0 ^@?6N_F)_V
M:O_Q-_G(JI>^QR^QBUH[Y(:AV\P9A&/U*V>13,-*. 9FLIH.&H?3>+)X<WWC
M,?KO@O]F*33=YNOSYEMX2P32 6]T=*K2KA77S/Z-:Z;RY-NL'&O&/JR=Y6OG
MQ9XZ!>JF_LTW3?&KO8<IWH@IQKC9PQS_9><8K@#T]@-)!'R7N?[UAQ[9FV)&
M/ZK)MH!QJZVH374!_+8?*998JR"K>Q(\B<?$4(M\NKD0P&O:]YV-[FZ-].V;
MX/_*_]OH'B "\2=K=%6:.*CIQR;W 'XK2)BFW1TUT^ DKB9!]XI+&\T1F@Z_
M@'3@<LO\4YR<H[Z,:?W?GO_ZF^C>_;+[^O5C@+/>_JO!:_CNSS*L![<>UNTM
M'M>O&9N_]+C6:(&O8ZW^M0>UU>X$G3GH'M6,Y4:?7TMBH>4(Z*&9AW;GM+7!
M0<L5DP:_W;.DP6\/28/OB8D]?=L?7D3 8!0T"4CUD^^/U[\'732"S;5P#%5N
M]V&3O%Y]DWS'%6OGY]E!]^@SAK0_##X>O_U_4$L#!!0    ( .>N"%67-J%0
M44T  -*T 0 5    =&TR,C(R.#4W9#%?97@T+3$N:'1M[7U[<]M6LN?_K.)W
MP*8F<Z4M6)'L.)G8'M=*EC+Q7L?V6DHRJ:FI6R !2HA!@ . DIE/O_T\+P 4
MY8<LVTK5C"41! [Z].EW__K13R<_/WL\'CWZZ6C_$/Z-\+]')T]/GAT]?O0-
M_PN??B,?/SIX<?A[='SR^[.COW\UJ\KV0;2WNVBCDWR>-='S[")Z5<V3,N8_
MQ-%Q5N>SK^"+\-675_W>PZC-WK1WDB(_+1]$=7YZUCZ,YDE]FL.O^.W=KQX_
M.GA\],^?GAX\/?EK.6D6#[_=V7OTS0$L_>5;/S1X M_WW6]XIZT6=%/SATG5
MMM5<_N:^ZC0KVZRFESL^>O7TZ#C:CYZ\^/GG%\_AX2^>_/=X]/*75T]^VC\^
MBG[;?_5J__E)_SMW[_DP>J_+_KC4^?'%\Q/O5=LZ*9M95<.WEHM%5D^3)B,J
M)HM%D6?I>)262=1,\ZR<X@KR<KK#E,-;?3BF@5N>[!\\.XJ>'#U[]G+_\/#I
M\W_\_:O=K^CWXY?[3_3W=R->EW0/HXL\;<_P7KM? R5.7NDCSK.ZS:=)H42%
M._A4_F/9M/ELA6?WT<FA?DUN=Q_O]EM2 [W;Z/@LJ;/F0?0__!](C</'W:_L
M?NW?O\AF#OOX7^E9AWD3>O33,F_SI(B.WL FYTT6'29M]D"DUX;_R7+CZ.[N
MW;NT I1S)Z]0[.%FW33Y(3?LW27Y8UZF&=TT+[]Z?/+3T^-H0_$1;;5G6?37
M(OW/LGKXZ!?=VD??_/+XKS7]<1N.'7#,+(>%MF=)&X,@J:/SI%AF49U-L_P\
M2V.E*?\7P05YVT1)T\!:F_ 9/U5%FM7N(\:CO(G@!?*VP)LM%U49X7?@M,_A
M-F4:-<O)']FT!6ZE#XI\GK=)FU=P=[@V4V[ 2_'S:56F.7]\EM597B8SN%?4
M9"VNOCV+HZ2%BU=1"_3&.\"*Z9+Q"+^> E/1%ZM9N/A>!O3(A6O@.R[J'/X?
MEGS_P>YNM-B9[S!+;.&&_U[5KZ,G><MKV,:O& +&XQ'PYO>/CG]Y^1BT&OX3
MKN,$2 .OA>_87<)DV49EU2(IZHS>*\9E !&;:9U/,MI"7.=B64_/0%9&L[J:
M1_LL+*/#Y_O1L<I*7O)3$)BPJB0ZS(KD HX]D+A>5#4O(%C;DVJ^ .*Z2\)-
MQ24(@S0D.:*MI'%W-DF1J^? "$3\)3 U+KR/0<<C%C[>:\-NP:/GL*#CMIJ^
MWHE.X*OF%6$WIAE>4Y49+R#\0D1/A <"-ZJ,@PN+(@*29?]9PK8+_^GNPX'"
MNP([-5&:S?(2J)?#W>"%@"Y,NKM;D^V=&VB67$&L[.[<1\'BZ5U\W)U9,L^+
MU8/+'DC7-OF?&:\/[O3+8X]&>[B/JHP[3W&_N2-7\?>N^O_K[PVK.L1-9,F!
M2]H9CYZ6P)<L3'3W62SI?F=%DUT@O^+.N[S#K#NKBJ*ZR,M3^=I9<I[1!_,L
M*>'/#7PM!87<,NO0#7S://C05LH[WY#_'YGD"MQDS_3^;)87N2_$QB.D3T-"
M^F56-Z014/ND.6B=MEB1DBG-;^U972U/S^APPR?SBO8#29ZE>5+GN'30"FU=
M%0U]M=%?0>5$DY7\C27 E(6"7# >7>3M693(.NBP-\OIF:HG>-*RX=U#F0K?
M:MIZ"7_@F[U:%IFX*+OWC8C)<).7-? 54'E_VMY@"?&.NWN0IQ%)R>[NQJ*(
M5J1Q^;RPF$ZSEA0<[PV=H[QN6I38_J&:%@D0GTV3B*U]L$BWDFTF0L[7>U(^
MQZNS$HR(ID77 )8 :\+S!Y<DT4F=I'CGGY/Z=2:'> +O8/1'YX;X$B07T)@
M+OC/,FM8+\H'98:ZJH5;@,%$-\?W)9V/'\L3QR-^)/[YXBQ'!EN_],BN'%BR
MSD ?MTRP@Z*JYI.L/HV>[;S<B;8F21.^WF&R8JW_PX-[NU'B&2?C46B=@.3[
M]L'NW4N,&%#SH.SX\PA(_^+DR?\[P%7B#__$U:-5TD_B\ZI8 ODN,O3V\8W
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M@>B:80PT[=K9G8I0>3!@3I\'-X[[DRM=UER'K&";BIS4DAHLSH(O76VTI=F
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M 1CPN ^G@O.,E9G<)>K\V5F*M!$Z:&;;T5;B&"XN"_A62P>&FF6*/U7%+3%
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MS,.TRCB-+KDNUXP2TT< *K621G/AC8/T69LU)6XQS4!KD28B?2D%7[9)JRX
M7[J]E6_'CDG0F^P*OW=O)_K-#4!*',7DZK&<P+ZM O($Q@5V2ZK*P 0TQ4-T
M^=J&YW5>!FN?*GB@]Q3*94M(;<WX-7EUF_+I^51!7SDRQ-BX925Y1%:F[CZX
MU4SPN!+(1XMIB&.\9M= ']W*A!OG #ZK&DS&@[DQ ^/H,,,8YU1CHC\CCHNI
M1G,S+IY],JV 4]A]0%M)+:PL!UJ&6-<ST[T^U#=+1\ .>2AP@?@3KB_UUS?W
MUN<CO]6V-B^:9G7+=1S:$&W;1OW3:D+$&'DD>\IY/H>)S0IBJH #5IB7TG)H
M.O?7H!3DK9D_'8QH;=WX8&<&-?N 8%.U$HBGHUB5J32<!DD-_)-$@_VN9H=
M'>)06%*(BNZQ'TR%]>#8IDN"]%V*(Q'SUY@BIF!XF8K/QS5" JEC5TIT*?)L
MN=&2;T7*C?/0CI-V66-!(<B58^P%7S% 84X_\4VR=NJ-I*<B1^2.Q0);=+.4
M$*/40VE-]HGB[.;\LR&PR&O#XD8[6Q6%X1RJ*Y8<6E[Z^8W$@XP1=%3NX. '
M*>@;E24J$ T_I!.8EW19"5O*F"^,?J1/($"AF\^R&T;9O_W"HNS?WD;9/P>)
M>/TC8_:U%CT%B4AVQB?D(>]=:9MZ[4*>RQ?W(,FY%EAGAF3+1@>F$VH%.J7
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M3   .JP! !4   !T;3(R,C(X-3=D,5]E>#0M,BYH=&WM?7MSV]:U[_^<X7?
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M6X(^/ZBKZDVQ O*\^&>TM_=P[UL38#-;NO[9'^^V_OS+_JM[7&&5 B^LAHJ
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M;[:&@M8O7%.:%5A9N H$+4OS= FV6O9;-EWB&[PZ^CZ:5@N*TLWSMA6UD3U
M^YZTI_PU:=MD>H&R8%LI\Z)JQ=@PZ\Q+=<7F6-\(CTDCCMJ';6'='[O=6SO1
M+Z"-\I)-"[!1P'"M\>*M7/1E>P6W?"C_<,PT5B);N;D.C9PEFG?X<^]"3 W5
M>9-+$N(4-1<6CIUF;5MP]/P5\#_HQJVD&8^&6[K2;;,L;C#<=CN'--X(C[>M
MB;!,W,(&-%KLE#B+KI,-I"^2\W/P:_$&09^9L8VD?ZY99%,N+I!=L.9:WU;!
M+GL5.Y2P2YH+(+3)*4PO,E E:9U<E6P/>X4GP"E)B7UR!?I_Y$+"[^D?YD47
M=05V)=8K><L+"*BVY"0#HJ'Q>+-WV1F/7F"L^,T#L%- 4,')Z7EA8T9H^5<,
M-JI2'(_'/$OAKWB0SI<)GN>,[60IEELMZ'[V._@*C-RD%H,2SP68.7"C/FK;
MQ^[@]^A%.Z;2"IG]7-I3]=A2"U-2KWH81(K<3"$;_$(+P0H\R^C)I]S ZHBG
M0!PLRQ8.MG-O$'-&W*5LCGI6GG1X@[,!$H'VPN0W3&9$+\5[3;#865DAI<#2
M;(G1_MQ4%<*3>E[/O$"T;OU4$YB4TZS@W OU=E7\IU/J#Q;OM!7>X?>!LTP'
MTO4<9T-LDS=Z')G.KO$9O0*A3H5]<K64KCAK!GHM"W(>4 <(<=FP'H_(K^#*
M/"H0KS"69J75!F1G>IF^Q&PVRSAW!0<)9)?(']<N[]Q>NV=U=<$3J#,.<[7
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MDX13K*'NDYLV\VCCQPPX0T457$^C!7=:BA]1Y;X?!22,$Q"V>:LN.<KYI:V
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M2H!UPT+KS;MM%T>N64Z8A,TFS@D8!Y1=P8+%NN-$Q"YTW+2:3W "G3M" #L
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M#G+=@?!.CD+<F$0 I>O(I.8"5<KM33,;K5G9<8F(ZQXZG6G'@0JCM\O2B?R
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M#\&S?\ECMYY$SW'X^YT)QGW R)BAS)<'+X_^2>G6'\Y^?/[L_P-02P,$%
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M,Q"!O XZ\O5R,M.J!YZT%(&-DA5^53?54J5RLW?+7(G[L?O(R!F%F[RL@*^
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M#E*8HB,>K6@?3Y*XY_D;MN5W]ZIP[EL&DS#=3/,9P]7#"F590'Y<UH9D<:>
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MS7P[:WJT^YWA3^$RA^&#4 A<V'']64D5VPNPU@Q,X81_INL @A2P33EO>(R
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M)C9J./NKMH%"?TCKRAJI:^60'ZI#N+-%@\'&;A\>'&]LZ<MQ! :CF+2QIL(
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M.,;KFPRTTIU,N'%NX*NRQIPY&!U3,)$.%48Z)SHR^@OH_-P4C;EY%\]*F93
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MNRU.M$KB/E0Y5KL@\JXDS(ZS1+L=&OV]H]/?*D8\^79A<BSIY45U8'MH"D1
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M10,I3E*DIQF51HH8;?TT/9&S'[''85!]Z&\"7/\K8^@/V]MZRXJ#3[.I(A
M_T]"(@J\](7GA5O9:YF]E?#S5QWQ$E::M\1.]WG[^?9V^^G3YT"FZ#H=+^E,
MZ/7/*WWO0\KSNQKV:WQS7-28>3A&0NN^HL6?J;_\GCND^WZ7[=&C1]_XA <1
MXTLN?WJ[XL*7S+XXDZ[X?NZ"'NABYB,6V:3?:_6_Z$J_#_M_4$L! A0#%
M  @ YZX(5;K9MOPV P  [ L  !$              ( !     &%P9&XM,C R
M,C X,#0N>'-D4$L! A0#%     @ YZX(56V'L-W_"@  ;(<  !4
M     ( !90,  &%P9&XM,C R,C X,#1?;&%B+GAM;%!+ 0(4 Q0    ( .>N
M"%7<]KXQ4@<  +M8   5              "  9<.  !A<&1N+3(P,C(P.# T
M7W!R92YX;6Q02P$"% ,4    " #GK@A57TBQ4Z(>  !]G   $@
M    @ $<%@  =&TR,C(R.#4W9#%?.&LN:'1M4$L! A0#%     @ YZX(5?V,
MB8$ME@  )4(# !8              ( ![C0  '1M,C(R,C@U-V0Q7V5X,3 M
M,2YH=&U02P$"% ,4    " #GK@A5ES:A4%%-  #2M $ %0
M@ %/RP  =&TR,C(R.#4W9#%?97@T+3$N:'1M4$L! A0#%     @ YZX(5;/+
M(7W73   .JP! !4              ( !TQ@! '1M,C(R,C@U-V0Q7V5X-"TR
M+FAT;5!+ 0(4 Q0    ( .>N"%5('?22XD@  $*C 0 5              "
M =UE 0!T;3(R,C(X-3=D,5]E>#0M,RYH=&U02P$"% ,4    " #GK@A5@7W:
M3-H-  #'+@  %@              @ 'RK@$ =&TR,C(R.#4W9#%?97@Y.2TQ
M+FAT;5!+ 0(4 Q0    ( .>N"%62G1JSK P  !8K   6              "
M 0"] 0!T;3(R,C(X-3=D,5]E>#DY+3(N:'1M4$L%!@     *  H F@(  .#)
$ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
